Research and development efficiency of pharmaceutical high-tech industry in different regions of China in recent years

doi:10.3969/j.issn.2096-045X.2023.01.021

Abstract

Abstract: Objective To compare research and development (R&D) efficiency of pharmaceutical high-tech industry in different regions of China in recent years. Methods The input and output data of pharmaceutical high-tech industry R&D from 2015 to 2019 were sorted out, and the data envelopment model was used to measure and analyze the R&D efficiency. Results Regional imbalance characteristic is found in R&D efficiency. Twenty-four regions have different degrees of scale excess. Room for improvement exists in R&D efficiency in 25 regions. Conclusion Universities and research institutions should strengthen the measurement and methodology research of R&D efficiency. Based on the analysis of the measurement results, local government will formulate precise and targeted encouragement policies to improve efficiency by reducing the input, optimizing the proportion of R&D input or strengthening the output target.

Key words: pharmaceutical high-tech industry, R&D efficiency, input, output, data envelopment analysis

CLC Number:

R956
G644

Liu Yang, Guo Xiangyu. Research and development efficiency of pharmaceutical high-tech industry in different regions of China in recent years[J]. Medical Education Management, 2023, 9(1): 116-121.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal06.magtechjournal.com/Jwk3_yyyzlt/EN/10.3969/j.issn.2096-045X.2023.01.021

https://journal06.magtechjournal.com/Jwk3_yyyzlt/EN/Y2023/V9/I1/116

References

［1］Ni J Y, Zhao J R, Ung C O L, et al. Obstacles and opportunities in Chinese pharmaceutical innovation［J］. Global Health, 2017, 13(1): 21.
［2］王广平, 石晟怡, 王颖, 等. 审评审批制度改革背景下医药产业组织结构调整路径研究［J］. 中国药事, 2019, 33(1): 1-11.
［3］Qiu L, Chen Z Y, Lu D Y, et al. Public funding and private investment for R&D: a survey in Chinas pharmaceutical industry［J］. Health Res Policy Syst, 2014, 12: 27.
［4］马恒, 饶惠霞. 广东省医药制造业研发资金投入影响的实证分析［J］. 发展改革理论与实践, 2018(6): 24-28.
［5］Qin X H, Du D B. Measuring universities’ R&D performance in China’s provinces: a multistage efficiency and effectiveness perspective［J］. Technol Anal Strateg Manag, 2018, 30(12): 1392-1408.
［6］李小平. 研发效率测度及其影响因素——评《中国与世界主要国家(地区)研发效率: 测度方法、国际比较及影响因素》［J］. 科技进步与对策, 2021, 38(10): 后插1.
［7］Dobrzanski P. The efficiency of spending on R&D in Latin America region［J］. Appl Econ, 2020, 52(46): 5020-5034.
［8］张曦, 郭淑芬. 中国工业技术创新效率的时空特征与动态演进［J］. 统计学报, 2021, 2(1): 61-70.
［9］张慧珍. 福建省科技创新效率研究——基于DEA方法的实证分析［J］. 石家庄铁道大学学报(社会科学版), 2021, 15(1): 22-27.
［10］Hashimoto A, Haneda S. Measuring the change in R&D efficiency of the Japanese pharmaceutical industry［J］. Res Policy, 2008, 37(10): 1829-1836.
［11］吉生保, 周小柯. 中国医药制造业研发效率研究——基于HMB生产率指数的经验证据［J］. 财经论丛, 2010(6): 10-15.
［12］洪进, 李敬飞, 李晓芬. 两阶段创新价值链视角下的我国医药制造业技术创新效率及影响因素分析［J］. 西北工业大学学报(社会科学版), 2013, 33(2): 51-56, 64.
［13］金安琪, 杨光, 李斐琳, 等. 基于DEA的中成药上市企业研发效率评价［J］. 中国现代中药, 2021, 23(4): 719-726.
［14］Thanassoulis E. Introduction to the theory and application of data envelopment analysis: a foundation text with integrated software［M］. New York: Springer, 2001.
［15］Banker R D, Charnes A, Cooper W W. Some models for estimating technical and scale inefficiencies in data envelopment analysis［J］. Manage Sci, 1984, 30(9): 1078-1092.